11.09.2007
Preliminary results have been obtained on the second phase of the clinical trials for the "Normogen" preparation. Stabilization of the tumor process with positive dynamics was observed for 80% of the patients who have various types of cancerous diseases. Moreover, the preparation showed a very high efficiency during the treatment of innocent tumors.

22.11.2006
An Agreement on carrying out of the second phase of Clinical Trials of the drug "Normogen" is concluded with Kazakhstan Scientific and Research Institute of Oncology and Radiology.

10.07.2006
Presented report of the 1st phase of clinical trial of drug "Normogen".

01.05.2006
The first phase of the Clinical Trials of Normogen in Kazakh Scientific and Research Institute of Oncology and Radiology was accomplished on May 1, 2006. The preparation Normogen was accepted as non-toxic, free of any adverse effect and safe for use.

01.05.2006
The first phase of the Clinical Trials of Normogen in Kazakh Scientific and Research Institute of Oncology and Radiology was accomplished. The preparation Normogen was accepted as non-toxic, free of any adverse effect and safe for use.

20.01.2006
An Agreement on carrying out of the first phase of Clinical Trials of the drug "Normogen" is concluded with Kazakhstan Scientific and Research Institute of Oncology and Radiology.

06.12.2005
Receiving of the first tranche under the Grant of Kazakhstan Innovation Fund.

22.11.2005
By the decision of the Expert Council, the Board of Directors and Managing Board of Kazakhstan Innovation Fund the company Real Med is given non-repayable, irrevocable grant in the amount of $ 250 000 USD intended for carrying out of Clinical Trials of "Normogen" drug.

17.11.2005
The Protocol of the Clinical Trials of "Normogen" to be carried out in Kazakhstan Scientific and Research Institute of Oncology and Radiology, is established by the Order of the Ministry of Health of the Republic of Kazakhstan. The Trials shall be carried out on volunteer oncologic patients, in two stages:
1. Study of the toxicity, safety and dose dependence of the drug. The study is to be carried out among the patients with generalized forms of malignant tumors resistant to all modern methods of treatment.
2. Study of the spectrum of antitumoral effect of the preparation "Normogen" among the patients with various etiology and localization of "signal" tumors: melanoma, leucosis, ovary cancer, hysterocarcinoma, testicle cancer, liver cancer, breast cancer, lung cancer, stomach cancer and rectal cancer.

01.11.2005, Astana, 15.11.2005, Almaty
The stand of "Real Med" company was presented at the Exhibition of Innovation Technologies. According to the results of the Exhibition, the product "Normogen" of "Real Med" company was recognized as the most forward-looking antitumoral drug among the exhibited preparations. By the decision of National Center of Certification of medicinal drugs of the Republic of Kazakhstan "Normogen" was recommended for carrying out of Clinical Trials.

10.06.2005
The Pharmacological Committee of the Republic of Kazakhstan gives an official permission for carrying out of Clinical Trials of the preparation "Normogen".

17.05.2004
The scientific work of Kazakhstan scientists, "The use of anti-idiotypic antibodies to alfa-fetoprotein for decomposition of changed cells", was recognized as the best one at the Second World-Wide Congress on Immunology and Allergy.